Bob Geho, CEO, Diasome discusses the current treatments for diabetes and the nearly 100 year history of insulin. He talks about the company's hepatocyte directed vesicle (HDV) nanotechnology that can be added to any insulin to lessen the instances of high and low blood sugar levels in people with diabetes. HDV nanotechnology can be added to any insulin to improve its safety and efficacy by targeting specific organs and in this case, restoring the liver's natural role in blood glucose control.
#Type1Diabetes #Type2Diabetes #Diabetes #Insulin
@diasome
Diasome.com
Empowered Patient Podcast